Levosimendan enhances cardiac performance after cardiopulmonary bypass: A prospective, randomized placebo-controlled trial

Journal of Cardiovascular Pharmacology

Volumn 34, Issue 2, 1999, Pages 219-228

  Nijhawan, Niraj ^a   Nicolosi, Alfred C ^a   Montgomery, Matthew W ^a   Aggarwal, Anil ^a   Pagel, Paul S ^a   Warltier, David C ^a,b  

^a CLEMENT J ZABLOCKI VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Inotropic drags; Left ventricular function; Myofilament calcium sensitizer

Indexed keywords

CALCIUM; LEVOSIMENDAN; MIDAZOLAM; SUFENTANIL; TROPONIN C; UNCLASSIFIED DRUG; VECURONIUM;

ADULT; AGED; ARTERIAL OXYGEN SATURATION; ARTICLE; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CONTRACTILITY; HEART OUTPUT; HEART RATE; HEART STROKE VOLUME; HUMAN; INOTROPISM; INTRAVENOUS DRUG ADMINISTRATION; LUNG VASCULAR RESISTANCE; MATHEMATICAL ANALYSIS; MEAN ARTERIAL PRESSURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC VASCULAR RESISTANCE; TREATMENT OUTCOME;

AGED; CARDIOPULMONARY BYPASS; CARDIOTONIC AGENTS; DOUBLE-BLIND METHOD; HEART; HEMODYNAMIC PROCESSES; HUMANS; HYDRAZONES; MIDDLE AGED; PROSPECTIVE STUDIES; PYRIDAZINES; VENTRICULAR FUNCTION, LEFT;

EID: 0032771929     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199908000-00007     Document Type: Article

References (30)

1. 2+ sensitizer, levosimendan, to recombinant human cardiac troponin C: a molecular modelling, fluorescence probe, and proton nuclear magnetic resonance study. J Biol Chem 1994;269:28584-90.
2. 2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ Res 1995;77:107-13.
3. Haikala H, Nissinen E, Etemadzadeh E, Levijoki J, Linden I-B. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation. J Cardiovasc Pharmacol 1995;25: 794-801.
4. Haikala H, Kaheinen P, Levijoki J, Linden I-B. The role of cAMP-and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan. Cardiovasc Res 1997;34: 536-46.
5. Haikala H, Kaivola J, Nissinen E, Wall P, Levijoki J, Linden I-B. Cardiac troponin C as a target for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol 1995;27:1859-66.
6. Haikala H, Linden I-B. Mechanisms of action of calcium-sensitizing drugs. J Cardiovasc Pharmacol 1995;26(suppl 1): S10-9.
7. Harkin CP, Pagel PS, Tessmer JP, Warltier DC. Systemic and coronary hemodynamic actions and left ventricular functional effects of levosimendan in conscious dogs. J Cardiovasc Pharmacol 1995;26:179-88.
8. Pagel PS, Harkin CP, Hettrick DA, Warltier DC. Zatebradine, a specific bradycardic agent, alters the hemodynamic and left ventricular mechanical actions of levosimendan, a new myofilament calcium sensitizer, in conscious dogs. J Pharmacol Exp Ther 1995; 275:127-35.
9. McGough MF, Pagel PS, Lowe D, Hettrick DA, Warltier DC. Levosimendan potentiates the inotropic actions of dopamine in conscious dogs. J Cardiovasc Pharmacol 1996;28:36-47.
10. Todaka K, Wang J, Yi G-H, et al. Effects of levosimendan on myocardial contractility and oxygen consumption. J Pharmacol Exp Ther 1996;279:120-7.
11. Pagel PS, McGough MF, Hettrick DA, et al. Levosimendan enhances left ventricular systolic and diastolic function in conscious dogs with pacing-induced cardiomyopathy. J Cardiovasc Pharmacol 1997;29:563-73.
12. Jamali IN, Kersten JR, Pagel PS, Hettrick DA, Warltier DC. Intracoronary levosimendan enhances contractile function of stunned myocardium. Anesth Analg 1997;85:23-9.
13. Lilleberg J, Sundberg S, Hayha M, Akkila J, Nieminen MS. Haemodynamic dose-efficacy of levosimendan in healthy volunteers. Eur J Clin Pharmacol 1994;47:267-74.
14. Lilleberg JM, Sundberg S, Leikola-Pelho T, Nieminen MS. Hemodynamic effects of the novel cardiotonic drug simendan: echocardiographic assessment in healthy volunteers. Cardiovasc Drugs Ther 1994;8:263-9.
15. Sundberg S, Lilleberg J, Nieminen MS, Lehtonen L. Hemodynamic and neurohumoral effects of levosimendan, a new calcium sensitizer, at rest and during exercise in healthy men. Am J Cardiol 1995;75:1061-6.
16. Lehtonen L, Mills-Owens P, Akkila J. Safety of levosimendan and other calcium sensitizers. J Cardiovasc Pharmacol 1995;26(suppl 1):S70-6.
17. Lilleberg J, Sundberg S, Nieminen MS. Dose-ranging study of a new calcium sensitizer, levosimendan, in patients with left ventricular dysfunction. J Cardiovasc Pharmacol 1995;26(suppl 1): S63-9.
18. Antila S, Eha J, Heinpalu M, et al. Hemodynamic interactions of a new calcium sensitizing drug levosimendan and captopril. Eur J Clin Pharmacol 1996;49:451-8.
19. McGough MF, Pagel PS, Lowe D, Hettrick DA, Kersten JR, Warltier DC. Effects of levosimendan on left ventricular function: correlation with plasma concentrations in conscious dogs. J Cardiothorac Vasc Anesth 1997;11:49-53.
20. De Hert SG, Rodrigus IE, Haenen LR, De Mulder PA, Gillebert TC. Recovery of systolic and diastolic left ventricular function early after cardiopulmonary bypass. Anesthesiology 1996;85: 1063-75.
21. Royster RL. Myocardial dysfunction following cardiopulmonary bypass: recovery patterns, predictors of inotropic need, theoretical concepts of inotropic administration. J Cardiothorac Vasc Anesth 1993;7(suppl 2):19-25.
22. Royster RL, Butterworth IV JF, Prielipp RC, et al. Combined inotropic effects of amrinone and epinephrine after cardiopulmonary bypass in humans. Anesth Analg 1993;77:662-72.
23. Hardy J-F, Searle N, Roy M, Perrault J. Amrinone, in combination with norepinephrine, is an effective first-line drug for difficult separation from cardiopulmonary bypass. Can J Anaesth 1993;40: 495-501.
24. Dupuis J-Y, Bondy R, Cattran C, Nathan HJ, Wynands JE. Amrinone and dobutamine as primary treatment of low cardiac output syndrome following coronary artery surgery: a comparison of their effects on hemodynamics and outcome. J Cardiothorac Vasc Anesth 1992;6:542-53.
25. Butterworth IV JF, Hines RL, Royster RL, James RL. A pharmacokinetic and pharmacodynamic evaluation of milrinone in adults undergoing cardiac surgery. Anesth Analg 1995;81:783-92.
26. Lilleberg J, Nieminen MS, Akkila J, et al. Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur Heart J 1998;19:660-8.
27. Pagel PS, Haikala H, Pentikainen PJ, et al. Pharmacology of levosimendan: a new myofilament calcium sensitizer. Cardiovasc Drug Rev 1996;14:286-316.
28. + channel in rat arterial myocytes. Eur J Pharmacol 1997;333: 249-59.
29. Butterworth JF IV, Royster RL, Prielipp RC, Lawless ST, Wallenhaupt SL. Amrinone in cardiac surgical patients with left-ventricular dysfunction: a prospective, randomized placebo-controlled trial. Chest 1993;104:1660-7.
30. De Hert SG, Moens MM, Jorens PG, Delrue GL, DePaep RJ, Vermeyen KM. Comparison of two different loading doses of milrinone for weaning from cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1995;9:264-71.